sponsored
PatientsVille.com Logo

PatientsVille

Solian Medical Research Studies

Up-to-date List of Solian Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Solian Medical Research Studies

Rank Status Study
1 Recruiting Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients
Conditions: Schizophrenia;   Treatment Resistant Disorders
Interventions: Drug: Clozapine;   Drug: Amisulpride;   Drug: Clozapine+Amisulpride
Outcome Measures: Change from baseline in Positive and Negative Syndrome Scale (PANSS);   Change from baseline in Clinical Global Impression - Severity (CGI-S);   Change from baseline in Beck Depression Inventory (BDI);   Change from baseline in Beck Anxiety Inventory (BAI);   Change from baseline in Schizophrenia Quality of Life Scale (SQLS);   Change from baseline in Simpson-Angus Scale (SAS);   Change from baseline in Clozapine Adverse Effects Inventory (CAEI)
2 Recruiting Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: Olanzapine;   Drug: Amisulpride;   Drug: Olanzapine and Amisulpride
Outcome Measures: Symptomatic improvement of schizophrenia after 8 weeks of treatment in comparison to time of inclusion of patient measured py Positive and Negative Symptom Scale (PANSS);   Symptomatic improvement of schizophrenia after 16 weeks of treatment in comparison to time of inclusion of patient measured py PANSS total score reduction;   Symptomatic improvement of schizophrenia from baseline to week 2 up to week 16 measured by PANSS total score reduction.;   PANSS total score reduction from baseline to week 2 as a predictor of the change after 8 weeks;   Serious adverse drug reactions;   Change of clinical condition measured by Clinical Global Impression Scale (CGI scale);   Change of the subjective well-being measured by Subjective Wellbeing under Neuroleptics Scale (SWN-K)
3 Recruiting Optimisation of Antipsychotic Drug Use in Older People
Conditions: Alzheimer's Disease;   Schizophrenia
Intervention: Drug: amisulpride
Outcome Measures: Dopamine D2/3 receptor occupancy at steady state (4 days) treatment with 50mg amisulpride;   Dopamine D2/3 receptor occupancy during 4-10 weeks treatment with 50-200mg amisulpride;   neuropsychological test performance
4 Unknown  Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Amisulpride;   Drug: placebo
Outcome Measures: Total score on the Positive and Negative Syndrome Scale;   Social and Occupational Functioning Assessment Scale;   Calgary Depression Rating Scale for Schizophrenia;   Schedule for the Assessment of Insight;   Service Engagement Scale;   Antipsychotic Non-Neurological Side Effects Scale
5 Recruiting The Effects of Dopamine on Reward Processing
Condition: Major Depressive Disorder (MDD)
Interventions: Drug: Amisulpride;   Drug: Placebo
Outcome Measures: Performance on a behavioral task assessing learning from positive and negative feedback.;   Brain activation during a task involving monetary rewards.;   Brain activation to social positive and negative feedback;   Ratings of mood and affect.
6 Recruiting An Investigation of Early Life Stress and Depression
Conditions: Major Depressive Disorder (MDD);   History of Childhood Sexual Abuse (CSA)
Interventions: Drug: Amisulpride;   Drug: Placebo
Outcome Measures: Event-related potentials (ERPs);   Behavioral Performance in Probabilistic Reward Task (PRT);   Cortisol levels;   Brain activity and structure (MRI Data);   Behavioral Performance in Monetary Incentive Delay (MID) task;   Behavioral performance in the Probabilistic Stimulus Selection Task (PSST);   Dopamine Transporter Levels;   Ratings of Mood and Affect
7 Recruiting Optimization of Treatment and Management of Schizophrenia in Europe
Conditions: Schizophrenia;   Schizophreniform Disorder;   Schizoaffective Disorder
Interventions: Drug: Amisulpride open label;   Drug: 6-week amisulpride double blind treatment;   Drug: 6-week olanzapine double blind treatment;   Drug: 12-week clozapine open-label treatment;   Behavioral: Psychosocial intervention
Outcome Measures: PANSS;   Sellwood rating scale;   Biological profile;   MRS measures;   SOFAS global functioning;   MRI assessments;   All cause treatment discontinuation;   All cause discontinuation;   Biological markers
8 Recruiting Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen
Conditions: Schizophrenia;   Schizophreniform Disorder;   Schizoaffective Disorder
Intervention: Drug: Amisulpride
Outcome Measures: Relationship between specific neuropsychiatric measures and global improvement on PANSS scores;   Effect of antipsychotic medication on the D2 binding potential (SPECT) in antipsychotic naive patients with schizophrenia.;   Effect of antipsychotic medication on P50-suppression;   Effect of antipsychotic medication on the human reward system;   Change in hippocampal and basal ganglia volume from baseline to follow-up.;   Change in processing speed over time after antipsychotic treatment.;   Change in levels of brain perfusion from baseline to follow-up.
9 Recruiting Bergen Psychosis Project 2 - The Best Intro Study
Conditions: Schizophrenia;   Psychotic Disorders
Interventions: Drug: Amisulpride;   Drug: Aripiprazole;   Drug: Olanzapine
Outcome Measure: Change of the Positive and Negative Syndrome Scale total score
10 Recruiting Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics
Condition: Schizophrenia
Interventions: Drug: SEP-363856;   Drug: Amisulpride;   Drug: Placebo
Outcome Measures: BOLD fMRI activity in key regions of interest (ROIs) while performing the Monetary Incentive Delay (MID), N-back, and Signal detection (SD) tasks after a single-dose of study medication;   Behavioural performance in the MID task, includes measurements of trial accuracy, trial duration, trial reaction time and amount of money won.;   Behavioural performance in the N-back task, includes measurements of accuracy (% correct for each trial type), reaction time and target sensitivity (d').;   Behavioural performance in the SD task, includes measurements of correct and incorrect responses.
11 Recruiting Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)
Condition: Schizophrenia
Interventions: Drug: amisulpride;   Drug: aripiprazole
Outcome Measures: Relationship between specific neuropsychiatric measures and global improvement on PANSS scores;   The relation between D2 binding potential (SPECT) and reward related brain activity (fMRI BOLD response) before and after D2 antagonism;   Time/dose improvement on P50 suppression after antipsychotic treatment;   Disturbances in reward related fMRI BOLD response in antipsychotic naive schizophrenic patients;   Hippocampal loss and basal ganglia increase after antipsychotic treatment;   Processing speed improvement over time after antipsychotic treatment;   The effect of D2 blockade on reward related fMRI BOLD response
12 Recruiting Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
Condition: Schizophrenia
Interventions: Drug: Cannabidiol CR;   Drug: Cannabidiol;   Drug: Amisulpride;   Drug: Olanzapine;   Drug: Quetiapine;   Drug: Risperidone;   Drug: Placebo
Outcome Measures: Plasma levels of cannabidiol;   Area Under Curve (AUC);   serum antipsychotic concentration
13 Recruiting The Switch Study - Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder
Intervention: Drug: Olanzapine or amisulpride
Outcome Measures: Number of patients in remission at week 8 comparing the "switched" with the "non switched" early non-responders);   PANSS total score change;   Cost of care;   Safety: Simpson-Angus Scale, Barnes Akathisia Scale, open interviews
14 Recruiting Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis
Condition: Psychosis Nos/Other
Interventions: Drug: Discontinuation antipsychotic treatment;   Drug: Antipsychotic treatment
Outcome Measure: Risk of relapse
15 Recruiting European Phase III Study of APD421 in PONV
Condition: PONV
Interventions: Drug: APD421;   Drug: Placebo
Outcome Measure: Complete Response (protection from PONV)
16 Recruiting US Phase III Study of APD421 in PONV
Condition: PONV
Interventions: Drug: APD421;   Drug: Placebo
Outcome Measure: Complete Response (protection from PONV)
17 Not yet recruiting A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients
Condition: Schizophrenia
Interventions: Drug: Cannabidiol;   Drug: Olanzapine;   Drug: Placebo Cannabidiol;   Drug: Placebo Olanzapine
Outcome Measures: Change in the Positive and Negative Syndrome Scale (PANSS) total score;   Changes in the PANSS subscores and clusters;   Changes in the Clinical Global Impression score;   Changes in the Global Assessment of Functioning Scale;   Changes in the Personal and Social Performance Scale;   Changes in the Calgary Depression Scale for Schizophrenia;   Changes in the Hamilton Anxiety Scale;   Changes in cognitive skills;   Response to antipsychotic medication;   Plasma levels of endogenous cannabinoids;   Changes in physiological parameter;   Changes in the UKU Side Effect Rating Scale;   Columbia Suicidality Severity Rating Scale
18 Unknown  Metabolic Side-effects for Second-generation Antipsychotics
Condition: Mental Disorders
Intervention:
Outcome Measure:

These studies may lead to new treatments and are adding insight into Solian etiology and treatment.

A major focus of Solian research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Solian